Lithobid

Quick links to important sections

Lithobid

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lithobid

Quick Facts

Property Description
Active Ingredient Lithium Carbonate (Li2CO3)
Form Extended-Release Tablet
Pharmacological Class Mood Stabilizer, Antimanic Agent
Common Use Maintaining emotional equilibrium
Origin Synthetic, Inorganic Salt

What is Lithobid and How is it Classified?

Lithobid is a specific prescription-only medication that contains the active ingredient Lithium Carbonate. It belongs to the pharmacological classes of Mood Stabilizer and Antimanic Agent. This medicine is clinically recognized for its role in providing stability to brain chemistry, which helps maintain a more consistent and even mood over time, particularly for individuals prone to extreme mood fluctuations. As a psychotropic agent, its general therapeutic purpose is to help individuals achieve and sustain emotional equilibrium. Its classification as an elemental ion therapy places it in a distinct pharmacological category, as its action involves the direct influence of a monovalent cation on fundamental signaling pathways.

Composition and The Extended-Release Form

The active ingredient in Lithobid is Lithium Carbonate, which is a synthetically produced inorganic salt. A differentiating factor of the Lithobid brand is its unique presentation as an Extended-Release Tablet for oral administration. This formulation contrasts with immediate-release lithium products. This specialized controlled-release formulation is engineered to deliver the active ingredient gradually over many hours. This type of formulation is designed to optimize the consistency of blood concentration and ensure patient adherence. This tablet form is used to help maintain a steady and reliable level of the active component in the body. The primary benefit of this design is to ensure a sustained therapeutic concentration of Lithium in the bloodstream, which is intended to support its stabilizing effects.

Regulatory References

  1. NIH MedlinePlus
  2. NIH-MedlinePlus
  3. European Medicines Agency (EMA)
  4. EMA Guidelines on Modified-Release

What side effects are possible with Lithobid?

Possible Side Effects and Safety Information

The safety profile of Lithobid (lithium carbonate) is characterized by a narrow therapeutic index, meaning the effective dose is close to the toxic dose. The primary safety concern is Lithium Toxicity, which may occur even at serum concentrations close to the therapeutic range.

Common and Expected Adverse Reactions

Adverse effects are often linked to serum concentrations, but some may occur during initial treatment and persist. Common reactions documented in regulatory sources include fine hand tremor, increased thirst (polydipsia), increased urination (polyuria), mild nausea, and general discomfort.

Serious Adverse Reactions and Organ System Effects

Lithium is associated with serious, potentially irreversible effects on several organ systems, necessitating continuous monitoring:

  • Renal Disorders: Risk of developing Nephrogenic Diabetes Insipidus (NDI) and Chronic Kidney Disease (CKD) with long-term use, requiring regular kidney function tests.
  • Endocrine Disorders: Potential for hypothyroidism and goiter, as well as hyperparathyroidism, requiring thyroid function monitoring.
  • Nervous System: Toxicity can lead to severe and sometimes persistent neurological problems, including ataxia, confusion, and in extreme cases, coma.
  • Cardiac Disorders: ECG changes are possible. There is a documented risk of fetal cardiac anomalies (e.g., Ebstein's anomaly) if used during the first trimester of pregnancy.

Safety Constraints and Monitoring

Due to its safety profile, Lithobid has specific regulatory constraints:

  • Mandatory Monitoring: Regular monitoring of serum lithium concentrations is required to mitigate toxicity risk.
  • Hydration/Sodium Balance: Patients must maintain normal fluid and sodium intake, as dehydration or sodium depletion can increase lithium retention and lead to toxicity.
  • Population Restrictions: The drug is generally avoided during the first trimester of pregnancy and requires caution and dose adjustments in the elderly and those with impaired renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

Lithium toxicity, the term for a Lithobid overdose, is a serious condition that can occur at serum concentrations only slightly above the established therapeutic range and carries a risk of death. The official regulatory profile documents a wide spectrum of manifestations and mandates specific emergency actions.

Documented Overdose Manifestations

Severity Documented Signs and Symptoms
Early/Mild Signs Fine tremor, vomiting, diarrhea, mild lack of coordination (ataxia), muscular weakness, drowsiness, giddiness.
Severe Outcomes Seizures, coma, respiratory failure, renal failure, irregular heart rhythms, and Serotonin Syndrome.

Required Emergency Actions

Immediate medical attention is required for any suspected toxicity. Regulatory guidance states that patients must discontinue Lithobid and contact a physician immediately upon recognizing early signs such as diarrhea, vomiting, or tremor. For serious symptoms, immediate emergency assistance must be sought.

Regulatory documents confirm that no specific antidote for lithium poisoning is known. Management focuses on supportive measures, including the potential need for hemodialysis to remove the compound from the blood in cases of moderate to severe toxicity. The risk of toxicity is heightened for elderly patients and those with underlying renal or cardiovascular disease, who may show signs of toxicity at lower concentrations.

Therapeutic Uses of Lithobid

What Lithobid Treats: Main Uses and Benefits

Lithobid is commonly used for managing mood stability to help manage the severe, heightened manifestations of acute manic episodes and for long-term maintenance treatment in Bipolar Disorder. The medication is used for easing the symptoms of manic episodes and for the management of the condition to reduce the frequency and intensity of mood fluctuations. These disruptive symptoms often include hyperactivity, extreme elation or irritability, rushed speech, and compromised judgment.

As a cornerstone long-term therapy, it supports a sustained state of emotional equilibrium by playing a role in the prevention of relapse into future manic and depressive episodes. It is commonly used to help with managing affective extremity and may be part of symptomatic management that addresses high-risk concerns in this patient group.

“The medication provides symptomatic support by helping to stabilize pronounced emotional and behavioral states.”

In supporting long-term stability, Lithobid provides support that helps ease the overall symptom burden on the patient's daily activities.


Quick Fact: Supportive management for Severe Mood Swings (Bipolar Disorder)

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lithobid?

This information reflects official regulatory classifications concerning patient eligibility and is not medical advice. The use of Lithobid (lithium carbonate extended-release) is governed by specific patient criteria, primarily focusing on organ function, fluid balance, and age.

Classification Population/Condition
Contraindicated Severe renal or cardiovascular disease, severe debilitation, dehydration, sodium depletion, or known hypersensitivity to any drug ingredient.
Generally Avoided Patients with Brugada Syndrome or suspected Brugada Syndrome.
Not Recommended Pediatric patients under 12 years of age (safety/effectiveness not established for this formulation).
Use with Extreme Caution Patients receiving diuretics or ACE inhibitors; or those with impaired renal function; or elderly patients.

Lithobid is contraindicated when conditions increase the risk of toxicity, specifically in cases of severe impairment of the kidneys or heart. Furthermore, its use is not recommended for children under 12 years of age. For women who are pregnant or breastfeeding, specific regulatory warnings exist: lithium may cause fetal harm, and nursing should generally not be undertaken as the drug is excreted in human milk. Restricted use applies to patients with milder renal impairment, requiring lower starting doses and frequent monitoring. The decision to use the medicine in a patient with a contraindication may only be considered in life-threatening situations where alternative treatments have failed, and requires daily serum lithium monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the co-administration of Lithobid with certain medications and substances. The primary concern across many interactions involves the potential for reduced renal clearance of lithium, leading to increased serum lithium concentrations and toxicity risk.

Documented Interacting Substances

Substance Category Clinical Constraint / Consequence
Diuretics (e.g., Thiazides) Reduced lithium excretion, increasing serum lithium concentration. Co-administration generally avoided; requires extreme caution.
NSAIDs (e.g., Indomethacin, Piroxicam) Can increase steady-state plasma lithium concentrations, necessitating close monitoring upon initiation or discontinuation.
ACE Inhibitors Can increase serum lithium concentration due to effects on renal clearance. Co-administration generally avoided; requires caution and monitoring.
Serotonergic Agents Increased risk of developing Serotonin Syndrome when combined with agents like SSRIs, SNRIs, or Triptans.
Antipsychotics (Neuroleptics) Co-administration has been associated with neurological adverse reactions; prompt discontinuation is necessary if signs of toxicity appear.
Metronidazole Reduced renal clearance of lithium, requiring close monitoring of serum concentrations.
Neuromuscular Blocking Agents Lithium may prolong the effect of these agents.

Monitoring and Procedural Requirements

Changes in concurrent medication, particularly with those affecting renal clearance (NSAIDs, Diuretics, ACE Inhibitors), mandate more frequent monitoring of serum lithium concentrations. Drugs that increase urinary lithium excretion (e.g., Acetazolamide, Urea) may decrease serum concentrations, also requiring close observation.

Mechanism of Action

Dual Inhibition of Intracellular Enzymes

The action of Lithobid (Lithium Carbonate) is based on the lithium ion ( Li^+) acting as a multimodal cellular modulator, primarily through its influence on two major, fundamental signaling systems within the central nervous system ( CNS). The lithium ion functions as a non-traditional mechanism-based agent by directly inhibiting key phosphatases. It targets Inositol Monophosphatase ( IMPase) and indirectly inhibits Glycogen Synthase Kinase-3 ( GSK-3). This dual action modifies cell signaling: IMPase inhibition causes a functional inositol depletion, which attenuates second-messenger systems and reduces signal amplification.

Structural Modulation of Neuronal Integrity

Simultaneously, GSK-3 inhibition modulates pathways linked to neuroplasticity and cellular structural maintenance. This mechanism influences cellular regulation beyond immediate chemical transmission by influencing the structural integrity and long-term functional regulation of nerve cells. The inhibition of GSK-3 enhances the expression of key growth factors like Brain-Derived Neurotrophic Factor ( BDNF) and anti-apoptotic factors. This cascade influences synaptic connectivity and processes governing overall neuronal integrity, resulting in a physiological effect linked to the sustained, homeostatic regulation of central nervous system ( CNS) function.

Dosage and Administration Information

Lithobid is an extended-release form of lithium carbonate that is administered exclusively by the oral route. Its use follows a structured, phased protocol, differentiating between initial stabilization and long-term continuation. Administration typically emphasizes the importance of maintaining the tablet's integrity; the extended-release tablet must be swallowed whole and should not be crushed, chewed, or broken, as this would compromise the controlled release of the active ingredient. It is also common for the medication to be taken with food or a liquid to help reduce the potential for gastrointestinal upset.

Common dosing patterns involve starting with a lower, introductory dose, often ranging from 600 mg to 900 mg daily, administered in a divided daily dose (two or three times a day). This initial phase, used for acute episodes, may involve doses adjusted up to a total of 1,800 mg per day. Once emotional equilibrium is achieved, the pattern transitions to long-term maintenance, where the usual total daily dose is 900 mg to 1,200 mg. For this maintenance phase, the dosing frequency is frequently consolidated to a once-daily schedule. Furthermore, specific usage principles involve dose reductions for certain groups; for example, adjustments are often noted for older adults (geriatric patients) and individuals with renal impairment, who typically require lower administered doses and careful oversight.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lithobid

Evidence for Use in Acute Manic Episodes

Research has explored the use of this therapy in short-term, placebo-controlled trials conducted during periods of increased symptom activity. Studies primarily monitored standardized rating scales that are used in research exploring how symptoms change over time. Findings from meta-analyses suggest patterns observed in the studies, where patterns of change in mania severity scales were described as distinguishable from those observed in the placebo groups. The research highlights changes measured during the study period for outcomes capturing phases of heightened symptom activity. Comparative evidence is lacking for direct head-to-head trials against all newer agents, and data for certain groups, such as children under the age of 7, remain insufficient for this specific indication.

Evidence for Long-Term Maintenance Therapy

Lithobid was evaluated in long-term research focusing on patients with conditions characterized by fluctuating or episodic manifestations. The data show patterns related to the prevention of future mood episodes, with studies consistently reporting that those continuing the therapy demonstrated a statistically longer time to relapse compared to those in comparator groups. Research has described patterns of protection against depressive episodes as less consistent than the patterns observed for preventing manic relapses. These findings describe group patterns, not personal outcomes, and the results apply only to the populations studied.

Research on Supporting Reduced Risk of Self-Harm

Research has been studied for its potential role in managing high-risk outcomes monitoring physiological strain or stress, specifically concerning self-harm and suicide-related behavior. Long-term observational evidence described an association related to the incidence of suicide attempts or deaths in the observed cohorts. Despite the observed patterns, certainty remains low in some specific areas, as the sample sizes were modest in dedicated trials, and the primary data for this specific area remain insufficient.

Evidence in Special Populations

The evidence base includes studies that have explored the use of the therapy in adolescents (ages 7–17) with Bipolar Disorder for acute symptom management. However, for other populations, such as older adults or patients with comorbidity-defined groups, the research is ongoing, and data are still emerging.

What is Still Uncertain About the Research

A primary research limitation is that the methods and rigor of older trials can differ from modern, large-scale RCTs, leading to variability in the evidence base. As noted, patterns of protection against depressive episodes are not as uniformly described as the patterns observed for manic relapses. Furthermore, research on the long-term functional outcomes that accompany chronic use is still developing. Data for certain groups remain insufficient.

Key Studies & References

  1. Bipolar disorder: assessment and management (NICE guideline CG185)

Frequently Asked Questions (FAQ)

Common questions about Lithobid (FAQ)

Q: Does Lithobid work immediately, or does it take time to feel the effects?

A: According to official product information, the effects of Lithobid are not immediate. It may take up to three weeks of continuous use before the full therapeutic effects begin to be noticed. Consistent administration is necessary to help maintain a stable blood level, which is vital for the drug to work as intended.


Q: How long does Lithobid stay in your system after you stop taking it?

A: Lithium is primarily eliminated from the body through the kidneys. While the exact elimination time (half-life) is not typically detailed in patient summaries, the drug requires daily administration to maintain stable therapeutic blood levels. The rate at which the drug leaves the body is closely linked to overall kidney function.


Q: What happens if I miss a dose of Lithobid?

A: Official guidance usually states that if a dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The guidance emphasizes that a missed dose should not be doubled, as this can increase the risk of toxicity.


Q: Are there any common over-the-counter medications that should not be taken with Lithobid?

A: Regulatory documents flag drug interactions with categories like NSAIDs (Nonsteroidal Anti-inflammatory Drugs), which include many common over-the-counter pain relievers such as ibuprofen or naproxen. Regulatory warnings indicate that these agents may increase the concentration of lithium in the blood and raise the risk of toxicity.


Q: Does drinking coffee or caffeine affect Lithobid levels?

A: Some patient guidance recommends caution or avoidance of drinks that contain caffeine, such as coffee, tea, and colas. This is because changes in hydration and electrolyte (salt) balance can be affected by caffeine intake, which may, in turn, affect lithium blood levels and potentially increase the risk of toxic effects.

--ุท

Q: Can certain diets or supplements interfere with Lithobid?

A: It is important that patients maintain a normal, consistent diet, especially regarding salt (sodium) intake, and stay well-hydrated. Significant changes in the amount of salt in the diet can alter the amount of lithium retained in the body, affecting its concentration. Significant dietary changes or starting new supplements should be discussed with a healthcare provider.


Q: How does Lithobid affect thyroid hormone levels?

A: Lithium use is associated with the potential for developing hypothyroidism (underactive thyroid) and goiter (enlargement of the thyroid gland). If these conditions occur, supplemental thyroid treatment may be considered. Therefore, regulatory protocols call for an evaluation of thyroid function before the medication is started.


Q: What are some signs that a Lithobid dose might be too high or too low?

A: Early signs of potential lithium toxicity (when the dose may be too high) can include diarrhea, vomiting, drowsiness, muscle weakness, and loss of coordination. A fine hand tremor can also be an indicator. Regulatory information focuses primarily on the signs of toxicity, rather than those for an insufficient dose.


Q: Can long-term use of Lithobid lead to permanent side effects?

A: Official warnings state that chronic use is associated with a risk of developing Chronic Kidney Disease (CKD). Furthermore, regulatory documents note the possibility of permanent neurological problems following severe, acute lithium toxicity.


Q: Can Lithobid make you feel tired or sleepy?

A: Drowsiness and fatigue are listed among the reported side effects associated with lithium treatment. It is also noted that increased drowsiness or lack of coordination can be early signs of potential lithium toxicity.


Q: Does Lithobid work for anxiety symptoms as well as mood swings?

A: The drug is officially indicated for the treatment of manic episodes of Bipolar Disorder and as a maintenance treatment to help reduce the frequency and intensity of subsequent episodes. It is not approved by regulatory agencies for use in treating general anxiety symptoms.


Q: Do children or adolescents take Lithobid, and if so, for what conditions?

A: The safety and effectiveness of the extended-release formulation of Lithobid has not been established for patients younger than 12 years of age. For patients 12 years of age and older, it is indicated for treating manic episodes and for long-term maintenance in those with Bipolar Disorder.


Q: What are the signs of dehydration that someone on Lithobid should watch for?

A: Because dehydration can increase the risk of lithium toxicity, regulatory guidance suggests that signs of dehydration to be aware of include dry mouth, dark urine, or producing very little urine. Dehydration may occur due to severe sweating, fever, vomiting, or diarrhea.


Q: Can Lithobid cause skin rashes or other dermatological issues?

A: Rash is listed among the possible side effects reported with lithium use. Patients are often monitored for dermatological changes, especially during initial treatment.


Q: Are headaches a common side effect of Lithobid?

A: Headaches are listed as a less common side effect in some regulatory summaries. It is noted that a sudden, severe headache can also be a sign of a rare but serious adverse event.


Q: Can people with high blood pressure take Lithobid safely?

A: Official information states that severe cardiovascular disease is a contraindication for using Lithobid. Furthermore, co-administration with ACE inhibitors (a common blood pressure medication) necessitates caution and monitoring due to the potential for increased lithium levels.


Q: How is Lithobid eliminated from the body?

A: Lithium is eliminated from the body almost entirely by the kidneys. This process, known as renal clearance, means that the drug's elimination rate is directly linked to kidney function. Because of this, lower doses and careful monitoring are often necessary for individuals with impaired kidney function.

How should Lithobid be stored and disposed of?

How to Store and Dispose of Lithobid?

The storage and disposal of Lithobid (lithium carbonate extended-release tablets) must follow official regulatory requirements to maintain product stability and safety.

Storage Requirements

Lithobid must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The tablets should be kept in a tightly closed container and protected from moisture and excessive heat. A mandatory safety requirement is that the medication must be stored out of the reach of children.

Official Disposal Protocol

Unused or expired Lithobid should be disposed of using a drug take-back program as the preferred method, according to government guidance. If this option is unavailable, the alternative is to mix the un-crushed tablets with an unpalatable substance (such as dirt or coffee grounds) and place the mixture in a sealed container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lithobid found in:

A-Z Index: